Brain-derived Neurotrophic Factor (BDNF) Genotyping
BDNF (Brain-derived neurotrophic factor) is a protein transcribed by the BDNF gene located 11p.14.1. The BDNF protein is expressed in the neurons of the central and peripheral nervous system and plays a vital role in neuronal growth, development, maturation, and survival. There are nine distinct promoter regions in the BDNF gene that transcribes pro-BDNF which then undergoes proteolytic splicing producing active BDNF. The protein is predominantly expressed in the hippocampus and cortical regions of the brain.
The BDNF is specifically responsible for making the synapses adaptable to experiences, termed ‘synaptic plasticity’. Poor synaptic plasticity can result from variants or polymorphisms in the BDNF gene due to diminished BDNF protein transcription and functionality. The poorly regulated synaptic plasticity manifests as a loss of intellectual behavior, understandability, and mental retardation. Variants in the BDNF gene are shown to be associated with bipolar disorders, suicidal tendencies, stress-mood disorders, and autism spectrum disorders.
The BDNF gene is furthermore linked to the responsiveness of anti-depressant therapies and animal model studies have shown that ventricular administration of BDNF exerts similar effects as that of conventional anti-depressants. Similarly, synergistic effects of BDNF with a variety of anti-depressant drugs have been found. Increased BDNF mRNA transcripts are found to correspond to and facilitate responses to lithium carbonate. On the other hand, a specific variant, rs6265, a Val66Met polymorphism on the 5’ pro-BDNF sequence is related to lithium carbonate non-responsiveness ( 81% of Caucasians, 56% of Asians). Expression of this gene is reduced in Alzheimer's, Parkinson's, and Huntington's disease patients.
- Aids in the investigation of neurological disorders related to intellectuality, and behavior
- Useful in predicting treatment resistance to anti-depressants including lithium
- Aids in the choice of appropriate anti-depressant therapy
BDNF rs6265 Val allele is associated with a poor response to lithium treatment of bipolar disorder and the BDNF 6265 Met allele occurs more frequently in good responders to lithium therapy.
- Low risk: A/G allele (heterozygous)
- High risk: A/A allele (homozygous)
A negative result indicates the absence of variant rs6265 in the BDNF gene.
Negative (No rs6265 polymorphism detected)
Whole blood (EDTA), buccal swab, saliva.
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
- Frozen: Unstable
Acceptable: extracted DNA (3microlitres in EB buffer; refrigerated)
- Science. 2006 Oct 6;314(5796):140-3. [PMID: 17023662]
- Neuropharmacology. 2016 Mar;102:72-9. [PMID: 26519901]
- J Neurosci. 2012 Mar 21;32(12):4092-101. [PMID: 22442074]
- Psychiatry. 2009 Jul;14(7):681-95. [PMID: 19153574]
- Front Neurosci. 2015 Jan 14;8:457. [PMID: 25642163]
- Per Med. 2013 Nov;10(8):777-784. [PMID: 29776284]
- J Psychopharmacol. 2021 Dec;35(12):1510-1516. [PMID: 34311608]